𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -19.7% S&P500 YTD: +8.3% TOTAL RETURNS (Jan 2022) Natan's portfolio: +79.2% *Benchmark: +37.3% S&P500: +64.6% MY POSITIONS: 26.8% | $TransMedics Group, Inc.(TMDX)$ 14.5% | $PROCEPT BioRobotics(PRCT)$ 14.2% |$PDD Holdings Inc(PDD)$ 11.8% | $Robinhood(HOOD)$ 11.1% | $Meta Platforms, Inc.(META)$ 6.8% | $Alibaba(BABA)$ 6.1% | $WIZZ AIR(WIZZ.UK)$ 3.8%

Natan YTD: -15.0% S&P500 YTD: +8.9% TOTAL RETURNS (Jan 2022) Natan's portfolio: +89.7% *Benchmark: +40.2% S&P500: +65.5% MY POSITIONS: 26.0% |$TransMedics Group, Inc.(TMDX)$ 15.8% | $PROCEPT BioRobotics(PRCT)$ 13.7% | $PDD Holdings Inc(PDD)$ 11.7% |$Robinhood(HOOD)$ 11.4% | $Meta Platforms, Inc.(META)$ 6.6% | $Alibaba(BABA)$ 6.3% | $Wizz Air Holdings PLC(WZZAF)$ 3.7% |

Natan YTD: -14.0% S&P500 YTD: +10.7% TOTAL RETURNS (Jan 2022) Natan's portfolio: +91.6% *Benchmark: +43.0% S&P500: +68.2% MY POSITIONS: 23.1% | $TransMedics Group, Inc.(TMDX)$ 13.9% | $PDD Holdings Inc(PDD)$ 13.1% | $Robinhood(HOOD)$ 12.3% |$PROCEPT BioRobotics(PRCT)$ 11.9% | $Meta Platforms, Inc.(META)$ 6.6% |$Wizz Air Holdings PLC(WZZAF)$ 6.5% | $Alibaba(BABA)$ 5.5% |

$TransMedics Group, Inc.(TMDX)$ IS EXTREMELY UNDERVALUED 😬 PRICE TARGET: $213 POTENTIAL UPSIDE: +216% ✅ ASSUMPTIONS: LTM Revenue: $0.636B 5Y Revenue CAGR: 20% 2031 Profit Margin: 24% 2031 PE Ratio: 40 Shares outstanding: 0.0409B Shares dilution: 2%/year VALUATION: Q1 2031 $TransMedics Group, Inc.(TMDX)$ SHARE PRICE =0.636 * (1.20)^5 * 0.24 * 40 /[0.0409 * (1.02)^5] = 336$ You can now choose the discount rate that you prefer, for Transmedics I want to use 12% ACTUAL PRICE: $68 FAIR VALUE: $191 PRICE TARGET (1Y): $214 POTENTIAL UPSIDE: +214% EXPECTED RETURNS: 37.6%/year DIVIDEND YIELD: - - - - - - - - - - - - - - - - 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭

𝙅𝙐𝙉𝙀 𝟮𝟬𝟮𝟲 𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -20.2% S&P500 YTD: +10.0% TOTAL RETURNS (Jan 2022) Natan's portfolio: +78.3% *Benchmark: +41.7% S&P500: +67.6% My positions: $TransMedics Group, Inc.(TMDX)$ $PDD Holdings Inc(PDD)$ $PROCEPT BioRobotics(PRCT)$ $Robinhood(HOOD)$ $Meta Platforms, Inc.(META)$ $Wizz Air Holdings PLC(WZZAF)$ $Alibaba(BABA)$

Natan YTD: -20.4% S&P500 YTD: +7.4% TOTAL RETURNS (Jan 2022) Natan's portfolio: +77.7% *Benchmark: +35.6% S&P500: +63.2% MY POSITIONS: 22.4% $TransMedics Group, Inc.(TMDX)$ 14.5% | $PROCEPT BioRobotics(PRCT)$ 13.7% | $PDD Holdings Inc(PDD)$ 12.6% | $Robinhood(HOOD)$ 10.7% | $Meta Platforms, Inc.(META)$ 7.4% | $WIZZ AIR(WIZZ.UK)$ 6.0% | $Alibaba(BABA)$ 5.7% |

1 It wasn’t easy to lose almost 20% since the beginning of the year, but I managed it. Change strategy? Absolutely not. I’m still outperforming the index over the long term, and I’m convinced that the stocks I own are worth much more than their current prices. No FOMO. $S&P 500(.SPX)$ 2 The funny part is that the stock that performed best during this selloff was $Moderna, Inc.(MRNA)$, which went 2x. Why? I honestly don’t know, especially considering that, among all of them, it’s probably the one that reported the weakest numbers. In the short term, the market increasingly feels like a roulette wheel. 3 My portfolio is experiencing its biggest drawdown in the last 3 year

𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -3.6% S&P500 YTD: +4.1% TOTAL RETURNS (Jan 2022) Natan's portfolio: +115.2% *Benchmark: +36.3% S&P500: +58.2% MY POSITIONS: 20.2% | $TransMedics Group, Inc.(TMDX)$ 16.0% | $PDD Holdings Inc(PDD)$ 13.0% | $Robinhood(HOOD)$ 10.7% | $Meta Platforms, Inc.(META)$ 8.9% | $Alibaba(BABA)$ 7.4% | $PROCEPT BioRobotics(PRCT)$ 7.3% | $PayPal(PYPL)$ 5.5% |

MY $TransMedics Group, Inc.(TMDX)$ VALUATION MODEL PRICE TARGET: $216 --> $220 POTENTIAL UPSIDE: +116% ✅ ASSUMPTIONS: LTM Revenue: $0.605B 5Y Revenue CAGR: 23% --> 22% 2030 Profit Margin: 24% 2030 PE Ratio: 40 Shares outstanding: 0.0409B Shares dilution: 2%/year VALUATION: Q4 2030 $TMDX SHARE PRICE = 0.605 * (1.22)^5 * 0.24 * 40 / [0.0409 * (1.02)^5] = 348$ You can now choose the discount rate that you prefer, for Transmedics I want to use 12% ACTUAL PRICE: $102 FAIR VALUE: $197 PRICE TARGET (1Y): $220 POTENTIAL UPSIDE: +116% EXPECTED RETURNS: 27.8%/year DIVIDEND YIELD: - 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘐'𝘮 𝘯𝘰𝘵 𝘢 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳 and all the 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘥 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥

Q1 2026 turned out to be my second worst quarter since 2022, with a -14.5% return. With many names down 30% in just one month, it was hard to do much better. My exposure to healthcare partially protected part of the portfolio. Given the numerous opportunities, I preferred to rotate that part of the healthcare allocation into more offensive stocks in order to take advantage of the current discounts. I’m extremely confident in my allocation and, based on my fair value estimates, I believe the portfolio can deliver a 24% CAGR over the next five years, a number from which a large part of my conviction comes. For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.